Patent US807991A successfully refreshed from Google Patents.
Patent US4866042A successfully refreshed from Google Patents.
US4866042A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method for the delivery of genetic material across the blood brain barrier
Assignee: Oregon Health & Science University
•
Filing: 1987-11-18
•
Granted: 1989-09-12
•
Expires: 2007-11-18
Abstract
Abstract A method for treating genetic and acquired brain disorders is disclosed in which genetic material is introduced into the blood stream for delivery to the brain. Prior to delivery, the interendothelial structure of the BBB is chemically altered to permit passage of the genetic material therethrough. This is accomplished through osmotic disruption of the BBB by administration of suitable chemical agents. Prior to administration, the genetic material can be inserted within the genome of a viral vector preferably incapable of replication in vivo. After crossing the blood brian barrier, the vector containing the genetic material enters the brain tissues where it delivers in a site-specific manner the genetic material in order to control adverse effects of the disease caused by defective genes. After delivery of the genetic material, the replication-defective character of the viral vector prevents its reproduction.
Inventors
- 👤 Edward A. Neuwelt
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-07 11:27
CPC Classifications
A; A61; A61K; A61K48/00; A61P; A61P25/00; A61P25/28
Claims Analysis
Total Claims: 7
Claim 1
Independent Claim
141 words
A method for the delivery and 2 incorporation of corrective genetic material into the cellular tissues of the brain of a human subject or other warm blooded animal subject for the treatment of genetic and acquired metabolic brain disorders, the method comprising the steps of: inserting genetic material designed to correct disorders of the brain into a virus; chemically disrupting the blood brain barrier of the subject so as to increase the permeability thereof; administering said virus containing said genetic material into the bloodstream of said subject for incorporation into the cellular tissues of said brain, said virus crossing the blood brain barrier of its increased permeability; and allowing said virus to deliver said genetic material into said cellular tissues of said brain, said genetic material being incorporated into said cellular tissues in order to treat said disorders of said brain.
Claim 2
Independent Claim
141 words
A method for the delivery and 2 incorporation of corrective genetic material into the cellular tissues of the brain of a human subject or other warm blooded animal subject for the treatment of genetic and acquired metabolic brain disorders, the method comprising the steps of: inserting genetic material designed to correct disorders of the brain into a virus; chemically disrupting the blood brain barrier of the subject so as to increase the permeability thereof; administering said virus containing said genetic material into the bloodstream of said subject for incorporation into the cellular tissues of said brain, said virus crossing the blood brain barrier of its increased permeability; and allowing said virus to deliver said genetic material into said cellular tissues of said brain, said genetic material being incorporated into said cellular tissues in order to treat said disorders of said brain.
Claim 3
Dependent Claim
14 words
The method of claim 1 wherein said virus is administered to said subject intravenously.
Claim 4
Dependent Claim
14 words
The method of claim 1 wherein said virus is administered to said subject intra-arterially.
Claim 5
Dependent Claim
30 words
The method of claim 1 wherein said chemical disruption of said blood brain barrier involves osmotic blood brain barrier modification through the administration of a pharmaceutically effective, non-toxic hypertonic solution.
Claim 6
Dependent Claim
22 words
The method of claim 4 wherein said hypertonic solution comprises a material selected from the group consisting of mannitol, arabinose, and glycerol.
Claim 7
Dependent Claim
26 words
The method of claim 1 wherein said administering of said virus is accomplished within about 1-2 minutes after said chemical disruption of said blood brain barrier.
References Cited (Backward Citations)
US4351831A
Cited
US4363793A
Cited
US4479932A
Cited
US4622218A
Cited
US4624846A
Cited
US4634586A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-09-11 | 1993-03-13 | 1993-09-12 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-09-11 | 1997-03-13 | 1997-09-12 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-09-11 | 2001-03-13 | 2001-09-12 | $7700.00 | Window Closed / Lapsed |